Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for political professionals · Sunday, May 27, 2018 · 448,828,125 Articles · 3+ Million Readers

Rockwell Medical Announces Triferic Presentations at the 2018 Asia Pacific Congress of Nephrology

/EIN News/ --

Oral and Poster Presentations for Triferic Clinical Pharmacology and Peritoneal Dialysis

Conference being held March 27-31, 2018, in Beijing China

WIXOM, Mich., March 20, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), announced today that four Triferic abstracts have been selected for presentation at the Asia Pacific Congress of Nephrology March 27-31, 2018, in Beijing China. Triferic is the Company’s novel iron replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis (HD). Triferic is the only FDA approved therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients

Presentation schedule at the APCN meeting:

Oral Presentation:  March 30, 2018
Clinical Pharmacology of Ferric Pyrophosphate Citrate (FPC, Triferic) in Chronic Hemodialysis Patients
Authors: Raymond Pratt and Ajay Gupta
               
Poster Presentations: Thursday, March 29 2018 at 10:45-11:15 and 15:30-16:00
Functional Iron Deficiency in CKD-HD: Ferric Pyrophosphate Citrate (FPC) bypasses the Hepcidin block and reduces ESA use.
Authors Ajay Gupta and Raymond Pratt

Pharmacokinetics of Ferric Pyrophosphate Citrate (Triferic, FPC) in CKD-5HD Patients.
Authors: Raymond Pratt and Ajay Gupta

Pharmacokinetics of Intraperitoneal Ferric Pyrophosphate Citrate (FPC, Triferic) in Peritoneal Dialysis Patients
Authors: Raymond Pratt and Ajay Gupta

Raymond D. Pratt, M.D., FACP, Chief Medical Officer of Rockwell Medical said, “The APCN meeting is an excellent opportunity to present Triferic data to a wide audience of nephrologists. This gives us a great avenue to connect with KOL’s from the Asia-Pacific region and to provide an educational introduction to our innovative anemia therapy. This is a timely event, as we will be initiating clinical trials of Triferic this year with our partner in China, Wanbang Pharma, with the intent to obtain marketing approval by 2020.” 

About Triferic
Triferic is the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. Delivered via dialysate, Triferic replaces the 5-7 mg iron loss that occurs in all patients during every dialysis treatment, effectively maintaining their iron balance and hemoglobin level. Unlike IV iron products, Triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and it is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming Functional Iron Deficiency in ESRD patients. Please visit www.triferic.com to view the Triferic mode-of-action (MOA) video and for more information.

About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.

Rockwell’s recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally.

Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.  Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities.

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Triferic® is a registered trademark of Rockwell Medical, Inc.

Investor Contact:
Michael Rice
LifeSci Advisors
(646) 597-6979
mrice@lifesciadvisors.com

Media Contact:
Matt Middleman
LifeSci Public Relations
(646) 627-8384
matt@lifescipublicrelations.com

Primary Logo

Powered by EIN News